In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling

Science Translational Medicine

Volumn 5, Issue 170, 2013, Pages

  Schneider, Anya ^a   Long, Sarah Alice ^a   Cerosaletti, Karen ^a   Ni, Chester T ^b   Samuels, Peter ^a   Kita, Mariko ^c   Buckner, Jane Hoyt ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b Virginia Mason Research Institute   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; UPREGULATION;

FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-6; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84874099546     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004970     Document Type: Article

References (36)

1. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35, 3343-3352 (2005).
2. high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123, 79-89 (2008).
3. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
4. U. Oh, G. Blevins, C. Griffith, N. Richert, D. Maric, C. R. Lee, H. McFarland, S. Jacobson, Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66, 471-479 (2009).
5. T. Korn, J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Bäckström, R. A. Sobel, K. W. Wucherpfennig, T. B. Strom, M. Oukka, V. K. Kuchroo, Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13, 423-431 (2007).
6. -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58, 2120-2130 (2008).
7. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353-359 (2008).
8. + regulatory T cells. J. Immunol. 181, 7350-7355 (2008).
9. J. M. van Amelsfort, J. A. van Roon, M. Noordegraaf, K. M. Jacobs, J. W. Bijlsma, F. P. Lafeber, L. S. Taams, Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 56, 732-742 (2007).
10. S. Haufe, M. Haug, C. Schepp, J. Kuemmerle-Deschner, S. Hansmann, N. Rieber, N. Tzaribachev, T. Hospach, J. Maier, G. E. Dannecker, U. Holzer, Impaired suppression of synovial fluid CD4+CD25- T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum. 63, 3153-3162 (2011).
11. E. J. Wehrens, G. Mijnheer, C. L. Duurland, M. Klein, J. Meerding, J. van Loosdregt, W. de Jager, B. Sawitzki, P. J. Coffer, B. Vastert, B. J. Prakken, F. van Wijk, Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118, 3538-3548 (2011).
12. W. A. Goodman, A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, K. D. Cooper, IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 183, 3170-3176 (2009).
13. J. Yang, M. O. Brook, M. Carvalho-Gaspar, J. Zhang, H. E. Ramon, M. H. Sayegh, K. J. Wood, L. A. Turka, N. D. Jones, Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. U.S.A. 104, 19954-19959 (2007).
14. W. A. Goodman, A. B. Young, T. S. McCormick, K. D. Cooper, A. D. Levine, Stat3 phospho-rylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186, 3336-3345 (2011).
15. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
16. W. E. Naugler, M. Karin, The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109-119 (2008).
17. K. Takeda, T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, S. Akira, Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161, 4652-4660 (1998).
18. E. B. Samoilova, J. L. Horton, B. Hilliard, T. S. Liu, Y. Chen, IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161, 6480-6486 (1998).
19. + T cells prevents development of experimental autoimmune diseases. J. Immunol. 180, 6070-6076 (2008).
20. E. Jakkula, V. Leppä, A. M. Sulonen, T. Varilo, S. Kallio, A. Kemppinen, S. Purcell, K. Koivisto, P. Tienari, M. L. Sumelahti, I. Elovaara, T. Pirttilä, M. Reunanen, A. Aromaa, A. B. Oturai, H. B. Søndergaard, H. F. Harbo, I. L. Mero, S. B. Gabriel, D. B. Mirel, S. L. Hauser, L. Kappos, C. Polman, P. L. De Jager, D. A. Hafler, M. J. Daly, A. Palotie, J. Saarela, L. Peltonen, Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 86, 285-291 (2010).
21. P. Bongioanni, S. Mosti, M. R. Romano, F. Lombardo, G. Moscato, G. Meucci, Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis. Eur. J. Neurol. 7, 291-297 (2000).
22. G. Frisullo, F. Angelucci, M. Caggiula, V. Nociti, R. Iorio, A. K. Patanella, C. Sancricca, M. Mirabella, P. A. Tonali, A. P. Batocchi, pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 84, 1027-1036 (2006).
23. + T cells. J. Autoimmun. 30, 293-302 (2008).
24. - cells. Proc. Natl. Acad. Sci. U.S.A. 102, 4103-4108 (2005).
25. D. Franciotta, G. Martino, E. Zardini, R. Furlan, R. Bergamaschi, L. Andreoni, V. Cosi, Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J. Neuroimmunol. 115, 192-198 (2001).
26. low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. J. Immunol. 180, 6411-6420 (2008).
27. J. M. van Amelsfort, K. M. Jacobs, J. W. Bijlsma, F. P. Lafeber, L. S. Taams, CD4+CD25+ regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50, 2775-2785 (2004).
28. J. Herrath, M. Müller, P. Amoudruz, P. Janson, J. Michaëlsson, P. T. Larsson, C. Trollmo, S. Raghavan, V. Malmström, The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur. J. Immunol. 41, 2279-2290 (2011).
29. high regulatory T cells in human autoimmune diabetes. J. Autoimmun. 24, 55-62 (2005).
30. J. Sanceau, J. Wijdenes, M. Revel, J. Wietzerbin, IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma. J. Immunol. 147, 2630-2637 (1991).
31. H. Takizawa, T. Ohtoshi, N. Yamashita, T. Oka, K. Ito, Interleukin 6-receptor expression on human bronchial epithelial cells: Regulation by IL-1 and IL-6. Am. J. Physiol. 270, L346-L352 (1996).
32. H-17 responses. Nat. Immunol. 9, 650-657 (2008).
33. T. Korn, E. Bettelli, M. Oukka, V. K. Kuchroo, IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
34. A. Schneider, J. H. Buckner, Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay. Methods Mol. Biol. 707, 233-241 (2011).
35. D. L Gruol, T. E. Nelson, Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15, 307-339 (1997).
36. C. H. Polman, S. C. Reingold, G. Edan, M. Filippi, H. P. Hartung, L. Kappos, F. D. Lublin, L. M. Metz, H. F. McFarland, P. W. O'Connor, M. Sandberg-Wollheim, A. J. Thompson, B. G. Weinshenker, J. S. Wolinsky, Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58, 840-846 (2005).